Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2014

01-05-2014 | Research Article

The Glu298Asp polymorphism in the NOS3 gene and the risk of prostate cancer

Authors: Yonggang Zhang, Qingyi Jia, Qing He, Jiani Shen, Jiqiao Yang, Pei Xue, Mengmeng Ma, Rui Xu, Liang Du

Published in: Tumor Biology | Issue 5/2014

Login to get access

Abstract

The Glu298Asp polymorphism in the NOS3 gene has been implicated as a risk factor for prostate cancer. To date, several studies have evaluated the associations between the Glu298Asp polymorphism and prostate cancer risk; however, the results were inconclusive. The aim of the current study was to perform a meta-analysis to investigate the association between the polymorphism and the risk of prostate cancer. A total of 3,206 cases and 3,880 controls from eight case-control studies were included for data synthesis. The overall results suggested no significant association between the polymorphism and the risk of prostate cancer (OR=1.01, 95 % CI=0.92–1.11, p = 0.83 for Asp/Asp+Glu/Asp vs. Glu/Glu). In the stratified analysis according to ethnicity, no significant associations were observed in Asians and Europeans. The current meta-analysis suggested that the Glu298Asp polymorphism of the NOS3 gene might not contribute to the risk of prostate cancer.
Literature
1.
2.
3.
4.
Brankovic A, Brajuskovic G, Nikolic Z, Vukotic V, Cerovic S, Savic-Pavicevic D, et al. Endothelial nitric oxide synthase gene polymorphisms and prostate cancer risk in Serbian population. Int J Exp Pathol. 2013. doi:10.​1111/​iep.​12045.PubMedPubMedCentral
5.
Jacobs EJ, Hsing AW, Bain EB, Stevens VL, Wang Y, Chen J, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomark Prev: Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2008;17(4):972–7. doi:10.​1158/​1055-9965.​EPI-07-2787.CrossRef
6.
Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, et al. Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev: Off J Eur Cancer Prev Organ. 2002;11(4):343–50.CrossRef
7.
Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the T-786C, G894T, and Intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer. Urol Oncol. 2012. doi:10.​1016/​j.​urolonc.​2012.​01.​002.PubMed
8.
Huang J, Yang J, Wang H, Xiong T, Zhang H, Ma Y, et al. The association between the poly(A) polymorphism in the VDR gene and cancer risk: a meta-analysis. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(3):1833–8. doi:10.​1007/​s13277-013-0724-0.CrossRef
9.
Liu C, Yin Q, Hu J, Li L, Zhang Y, Wang Y. A meta-analysis of evidences on XPC polymorphisms and lung cancer susceptibility. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(2):1205–13. doi:10.​1007/​s13277-013-0663-9.CrossRef
10.
Zhang YG, Li XB, Zhang J, Huang J, He C, Tian C, et al. The I/D polymorphism of angiotensin-converting enzyme gene and asthma risk: a meta-analysis. Allergy. 2011;66(2):197–205.CrossRefPubMed
11.
12.
Cheng ZG, Zhou W, Tao ZH, Chen W. Associaiton of endothelial nitric oxide cynthase gene polymorphism with prostae cancer. Zhong Guo Nan Ke Xue Za Zhi. 2011;25(7):18–21.
13.
Ziaei SA, Samzadeh M, Jamaldini SH, Afshari M, Haghdoost AA, Hasanzad M. Endothelial nitric oxide synthase Glu298Asp polymorphism as a risk factor for prostate cancer. Int J Biol Mark. 2013;28(1):43–8. doi:10.​5301/​JBM.​2012.​9585.CrossRef
Metadata
Title
The Glu298Asp polymorphism in the NOS3 gene and the risk of prostate cancer
Authors
Yonggang Zhang
Qingyi Jia
Qing He
Jiani Shen
Jiqiao Yang
Pei Xue
Mengmeng Ma
Rui Xu
Liang Du
Publication date
01-05-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1619-4

Other articles of this Issue 5/2014

Tumor Biology 5/2014 Go to the issue

Research Article

Early molecular response in chronic myeloid leukemia patients predicts future response status

Research Article

INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells

Research Article

Survivin mRNA-circulating tumor cells predict treatment efficacy of chemotherapy and survival for advanced non-small cell lung cancer patients

Research Article

Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease

Research Article

The co-expression of telomerase and ALT pathway in human breast cancer tissues

Research Article

The effect of CYP1A1 and CYP1A2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits